8-K: BioCardia Faces Potential Nasdaq Delisting After Failing to Meet Market Value and Bid Price Requirements

BioCardia, Inc. is facing potential delisting from the Nasdaq Capital Market after failing to meet minimum market value and bid price requirements, and has requested a hearing to appeal the decision.

Summary

• BioCardia, Inc. received a notice from Nasdaq on September 6, 2023, stating that its Market Value of Listed Securities (MVLS) fell below the required $35 million minimum.
• The company was given until March 4, 2024, to regain compliance with the MVLS requirement.
• On March 6, 2024, Nasdaq informed BioCardia that it had not regained compliance and would be delisted unless an appeal was filed by March 13, 2024.
• Separately, on September 13, 2023, BioCardia received notice that it was not in compliance with the minimum bid price requirement.
• The company had until March 11, 2024, to regain compliance with the minimum bid price requirement.
• On March 12, 2024, Nasdaq confirmed that BioCardia had also failed to meet the minimum bid price requirement.
• BioCardia has requested a hearing with a Nasdaq Hearings Panel to appeal both delisting determinations.
• The hearing request will stay any delisting or suspension of the company's securities pending the Panel's decision.
• There is no guarantee that the Panel will grant the company's request for continued listing or that the company will be able to regain compliance.

Sentiment

Score: 3

Explanation: The document indicates significant negative news regarding the company's listing status, with a high risk of delisting. The company's future is uncertain, and the potential for negative impacts on shareholders is high.

Positives

• BioCardia has requested a hearing to appeal the delisting decisions, which will temporarily prevent the delisting of its securities.
• The company will present a plan to regain compliance with both the MVLS and minimum bid price requirements to the Nasdaq Hearings Panel.

Negatives

• BioCardia failed to meet the minimum Market Value of Listed Securities (MVLS) requirement of $35 million.
• The company also failed to meet the minimum bid price requirement.
• There is no assurance that the Nasdaq Hearings Panel will grant the company's request for continued listing.
• Delisting could make it more difficult to buy or sell the company's securities and could lead to a material decline in the stock price.
• Delisting could also impair the company's ability to raise capital and trigger defaults under existing agreements.

Risks

• The company may not be able to convince the Nasdaq Hearings Panel to grant continued listing.
• Even if the appeal is successful, the company may not be able to regain compliance with the Nasdaq listing requirements.
• Delisting from the Nasdaq Capital Market could significantly negatively impact the company's stock price and ability to raise capital.
• Delisting could trigger defaults and penalties under outstanding agreements.

Future Outlook

The company intends to present a plan to regain compliance with both the MVLS and minimum bid price requirements to the Nasdaq Hearings Panel, but there is no guarantee of success.

Management Comments

• The company will present a plan to regain compliance with respect to both the MVLS Requirement and the Minimum Bid Price Requirement before the Panel.

Industry Context

This situation is not uncommon for smaller biotech companies that may face challenges in maintaining market capitalization and stock price, especially during periods of market volatility or when facing regulatory hurdles.

Comparison to Industry Standards

• Many small-cap biotech companies face similar challenges in maintaining Nasdaq listing compliance, particularly those with volatile stock prices or limited revenue.
• Companies like Athersys and Ocugen have also faced delisting notices in the past due to similar issues with market capitalization and bid price.
• The Nasdaq Capital Market has specific requirements for continued listing, and companies that fail to meet these requirements face potential delisting.

Stakeholder Impact

• Shareholders face the risk of significant losses if the company is delisted.
• Employees may experience uncertainty about the company's future.
• The company's ability to raise capital may be impaired, potentially affecting future operations and growth.

Next Steps

• BioCardia will present its plan to regain compliance to the Nasdaq Hearings Panel.
• The Nasdaq Hearings Panel will make a decision regarding the company's continued listing.

Key Dates

Keywords

delisting, Nasdaq, compliance, market value, minimum bid price, hearing, appeal, securities, BCDA